166 EFFECT OF ANTIMUSCARINIC DRUGS ON COGNITIVE FUNCTIONS IN THE MANAGEMENT OF OVERACTIVE BLADDER IN ELDERLY

166 EFFECT OF ANTIMUSCARINIC DRUGS ON COGNITIVE FUNCTIONS IN THE MANAGEMENT OF OVERACTIVE BLADDER IN ELDERLY

Bibliographic Details
Main Authors:	E Rangganata, F Widia, H Rahardjo
Format:	Article
Language:	English
Published:	Elsevier 2022-06-01
Series:	Continence
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772973722005677

Similar Items

Effect of Antimuscarinic Drugs on Cognitive Functions in the Management of Overactive Bladder in Elderly
by: Ervandy Rangganata, et al.
Published: (2020-10-01)

An Overview of the Clinical Use of Antimuscarinics in the Treatment of Overactive Bladder
by: Anastasios Athanasopoulos, et al.
Published: (2011-01-01)

Maintenance of the Therapeutic Effect of Two High-Dosage Antimuscarinics in the Management of Overactive Bladder in Elderly Women
by: Kirill Kosilov, et al.
Published: (2013-12-01)

A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder
by: Creanga Dana, et al.
Published: (2009-07-01)

Patterns of use of antimuscarinic drugs to treat overactive bladder in Denmark, Sweden, and the United Kingdom.
by: Andrea V Margulis, et al.
Published: (2018-01-01)

Comparative study of different combinations of mirabegron and antimuscarinics in treatment for overactive bladder syndrome in elderly patients
by: Yuh-Chen Kuo, et al.
Published: (2023-01-01)

Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data
by: Elena Andretta, et al.
Published: (2022-09-01)

Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin
by: Bilal Chughtai, et al.
Published: (2008-09-01)

Factors associated with antimuscarinic drug persistence and increasing drug persistence after switching to mirabegron for overactive bladder patients
by: Chung-Cheng Wang, et al.
Published: (2019-01-01)

Exposure to antimuscarinic medications for treatment of overactive bladder and risk of lung cancer and colon cancer
by: Löfling L, et al.
Published: (2019-01-01)

Comparisons of the therapeutic safety of seven oral antimuscarinic drugs in patients with overactive bladder: a network meta-analysis
by: Nannan Yang, et al.
Published: (2021-09-01)

Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach.
by: Thomas M Kessler, et al.
Published: (2011-01-01)

Cost-effectiveness of solifenacin compared with oral antimuscarinic agents for the treatment of patients with overactive bladder in the UK
by: Zalmai Hakimi, et al.
Published: (2018-01-01)

Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: A decision-tree model
by: Trocio Jeffrey, et al.
Published: (2011-05-01)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)

Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence
by: Ravelo Arliene, et al.
Published: (2009-11-01)

Use of Antimuscarinics in the Elderly
by: Bhavin Patel, et al.
Published: (2009-01-01)

Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
by: Sheng-Mou Hsiao, et al.
Published: (2015-09-01)

Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin
by: Marloes J. Tijnagel, et al.
Published: (2017-04-01)

Characterization of Bladder Selectivity of Antimuscarinic Agents on the Basis of Drug-Receptor Binding
by: Shizuo Yamada, et al.
Published: (2012-09-01)

Bladder contractility index changes with short-term antimuscarinic therapy in patients with detrusor overactivity: A placebo controlled randomised study
by: Alka Ashok Bhide, et al.
Published: (2023-12-01)

Overactive bladder in the vulnerable elderly
by: Wolff GF, et al.
Published: (2014-10-01)

The Forefront for Novel Therapeutic Agents Based on the Pathophysiology of Lower Urinary Tract Dysfunction: Bladder Selectivity Based on In Vivo Drug–Receptor Binding Characteristics of Antimuscarinic Agents for Treatment of Overactive Bladder
by: Akira Yoshida, et al.
Published: (2010-01-01)

Comparative persistence, switch rates, and predictors for discontinuation of antimuscarinics for overactive bladder: A 10-year nationwide population-based study in Taiwan
by: Hao-Wei Chen, et al.
Published: (2018-01-01)

Protective Effects of Antimuscarinics on the Bladder Remodeling After Bladder Outlet Obstruction
by: Qiang Liu, et al.
Published: (2017-11-01)

Editorial Comment: Comparative Persistence, Switch Rates, and Predictors for Discontinuation of Antimuscarinics for Overactive Bladder: A 10-year Nationwide Population-based Study in Taiwan
by: En Meng
Published: (2018-01-01)

Efficacy, according to urodynamics, of OnabotulinumtoxinA compared with antimuscarinic drugs, for neurogenic detrusor overactivity: a systematic review and network meta-analysis
by: Rui Xu, et al.
Published: (2022-10-01)

Efficacy and safety of dose escalation in male patients with overactive bladder showing poor efficacy after low-dose antimuscarinic treatment: A retrospective multicenter study
by: Myungsun Shim, et al.
Published: (2020-11-01)

Studies of relationships between overactive bladder and frailty in the elderly
by: M. Yoshida, et al.
Published: (2020-07-01)

Pharmacologic management of overactive bladder
by: Sum Lam, et al.
Published: (2007-10-01)

Update on the management of overactive bladder
by: Christina Fontaine, et al.
Published: (2021-08-01)

Medical management of overactive bladder
by: Sarvpreet S Ubee, et al.
Published: (2010-01-01)

The Antimuscarinic Agent Tolterodine Regulates Bladder Extracellular Matrix in Partial Bladder Outlet Obstruction in Rats
by: Tong-Xin Yang, et al.
Published: (2018-03-01)

The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial
by: Jose E. Batista, et al.
Published: (2015-08-01)

The overactive bladder
by: Richard Foon, et al.
Published: (2010-08-01)

Overactive bladder
by: Anna Zwierzyńska
Published: (2021-07-01)

Transdermal drug delivery treatment for overactive bladder
by: Roger R. Dmochowski, et al.
Published: (2006-10-01)

Comparisons of urinary bladder responses to common antimuscarinics reveals unique effects of darifenacin
by: Vineesha Veer, et al.
Published: (2025-02-01)

Mirabegron in the Management of Overactive Bladder Syndrome
by: O'Kane M, et al.
Published: (2022-09-01)

Comment on: update on the management of overactive bladder
by: David Staskin
Published: (2022-01-01)